Table 1.
Description of 66,369 participants in the study at enrollment.*
| N (%) | ||
|---|---|---|
| Age | ||
| 15–34 | 25170 (37.9 %) | |
| 35–49 | 30833 (46.5 %) | |
| >=50 | 10366 (15.6 %) | |
| Group, by sex, exposure, sub-Saharan Africa immigration | ||
| MSM, not a migrant | 20890 (31.5 %) | |
| IDU, not a migrant | 8429 (12.7 %) | |
| Other men, not a migrant | 13982(21.1 %) | |
| Other women, not a migrant | 13073 (19.7 %) | |
| MSM, migrant | 180 (0.3 %) | |
| IDU, migrant | 83 (0.1 %) | |
| Other men, migrant | 3732 (5.6 %) | |
| Other women, migrant | 6000 (9.0 %) | |
| CD4 cell count | ||
| unknown | 2155 | |
| 0–49 | 3722 (5.8 %) | |
| 50–99 | 2203 (3.4 %) | |
| 100–199 | 4305 (6.7 %) | |
| 200–349 | 9439 (14.7 %) | |
| 350–499 | 34166 (53.2 %) | |
| >=500 | 10379 (16.2 %) | |
| HIV-RNA in copies/mL | ||
| Missing | 15594 | |
| <500 | 24972 (49.1 %) | |
| 500–4999 | 6844 (13.5 %) | |
| 5000–49999 | 9836 (19.4 %) | |
| >=50000 | 9123 (18.0 %) | |
| AIDS | ||
| No | 56134 (84.6%) | |
| Yes | 10235 (15.4%) | |
| PJP prophylaxis | ||
| No | 40805 (61.5 %) | |
| Yes | 25564 (38.5 %) | |
| Calendar year | ||
| 1992–1995 | 12498 (18.8 %) | |
| 1996–1999 | 7029 (10.6 %) | |
| 2000–2009 | 46842 (70.6 %) | |
| Duration of cART | ||
| no cART, year<1996 | 13788 (20.8 %) | |
| no cART, year ≥1996 | 12498 (18.8 %) | |
| ≤1 month | 681 (1.0 %) | |
| 2 months | 774 (1.2 %) | |
| 3 months | 686 (1.0 %) | |
| 4–6 months | 1771 (2.7 %) | |
| >6 months | 36171 (54.5 %) | |
*
Abbreviations: PY, person-years; MSM, men who have sex with men; IDU, injection drug use; AIDS, acquired immunodeficiency syndrome; HIV-RNA, human immunodeficiency virus plasma viral load; PJP, Pneumocystis jiroveci pneumonia;cART, combination antiretroviral therapy. Prophylaxis is use of trimethoprim-sulfamethoxazole, dapsone or aerosolized pentamidine with no prior history of PJP.